Hytrin 2 (Terazosin Hydrochloride Dihydrate)

Terazosin selectively blocks alpha‑1 adrenergic receptors on vascular smooth muscle and in the prostate. By preventing norepinephrine from binding these receptors, it induces vasodilation, which reduces peripheral resistance and lowers systemic blood pressure. In the lower urinary tract, receptor blockade relaxes smooth muscle of the prostate and bladder neck, facilitating urine passage and relieving symptoms of BPH.

The appropriate dose of Hytrin 2 is determined by the prescribing physician based on the patient’s condition, response to therapy, and any concomitant medications. Dosage may start at a low level and be titrated upward to achieve the desired blood pressure control or urinary symptom relief while minimizing side effects. Patients should follow the exact regimen provided on the prescription label.

The safety of terazosin in pregnancy and lactation has not been established, and it is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To request Hytrin 2, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing a formal quotation, availability, shipping terms (including any temperature requirements), and assistance with import documentation.

Compared with non‑selective alpha blockers or other classes such as ACE inhibitors, terazosin offers the dual benefit of blood‑pressure reduction and relief of urinary obstruction in men with BPH. However, it may cause more pronounced first‑dose orthostatic hypotension than some alternatives. Choice of therapy depends on the patient’s overall cardiovascular profile, comorbidities, and whether concurrent management of BPH is required.

Hytrin 2 tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged. No refrigeration is required, and the tablets remain stable for the shelf‑life indicated on the label when stored under these conditions.

Hytrin 2 is taken orally, usually with a full glass of water. The tablet may be taken with or without food, but patients are often advised to take the first dose at bedtime to reduce the risk of dizziness from postural hypotension. The exact timing and frequency should follow the prescribing clinician’s instructions, and the medication should be swallowed whole, not chewed or crushed.

The most serious adverse events linked to terazosin include severe hypotension that can lead to fainting, priapism (a prolonged, painful erection), and rare but potentially life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden loss of consciousness, a painful erection lasting more than four hours, or signs of a severe allergic response like swelling of the face, lips, or throat.

Hytrin 2 is contraindicated in individuals with known hypersensitivity to terazosin or any component of the formulation. It should be avoided in patients with severe hepatic impairment, those who have experienced a recent myocardial infarction or unstable angina, and in patients taking other alpha‑1 blockers due to the risk of additive hypotension. Pregnant or nursing women should only use it if the potential benefits outweigh the risks, after thorough consultation with a healthcare professional.